Healthy
Conditions
Keywords
bioequivalence, Ondansetron ODT, Fasting, To determine bioequivalence under fasting conditions
Brief summary
To compare the single-dose bioavailability of Ondansetron 8 mg oDT and Zofran 8 mg ODT
Detailed description
To Compare the single-dose bioavailability of Kali's Ondansetron 8 mg ODT with that of GlaxoSmithKine's Zofran 8 mg ODT under fasting conditions
Interventions
DRUGOndansetron
ODT, 8 mg, single-dose
DRUGZofran
ODT, 8 mg, fasting conditions
Sponsors
Algorithme Pharma Inc
Par Pharmaceutical, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Subjects meeting all of the following criteria may be included in the study. * Availability of subject for the entire study period and willingness to adhere to protocol requirements as evidenced by the informed consent form duly signed by the subject. * Males and Females aged from 18 to 50 years ol with a body mass index (BMI)within 19-30; demographic data (sex, age, ethnic group, body weight, height and smoking habits) will be recorded and reported in the final report. * Clinical laboratory values within the laboratory's stated normal range; if not within this range, they must be without any clinical significance and must be recorded as such in the CRF (laboratory tests are presented in section 7.1.3. * Healthy according to the laboratory results and physical examination. * Normal cardiovascular function according to ECG. * Non or ex-smokers.
Exclusion criteria
* Significant history of hypersensitivity to ondansetron or any related products as well as severe hypersensitivity reactions (like angioedema) to any drugs. * Presence or history of significant gastrointestinal, liver or kidney disease, or any conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects. * Presence or history of significant cardiovascular, pulmonary, hematologic, neurologic, psychiatric, endocrine, immunologic or dermatologic disease. * Females who are pregnant, lactating or are likely to become pregnant during the study phases. * Females of childbearing potential who refuse to use an acceptable contraceptive regimen throughout the body. * Positive pregnancy test before and during the study. * Maintenance therapy with any drug, or significant history or drug dependancy, alcohol abuse (\>3 units of alcohol per day, intake of excessive alcohol, acute or chronic), or serious psychological disease. * Any clinically significant illness in the previous 28 days before day 1 of this study. * Use of enzyme-modifying drugs in the previous 28 days before 1 day of this study (all barbiturates, corticosteroids, phenylhydantoins, etc.). * Participation in another clinical trial in the previous 28 days before day 1 of this study. * Donation of 500 mL of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the previous 56 days before day 1 of this study. * Positive urine screening of drugs of abuse (drug names are presented in section 7.1.4). * Positive results to HIV, HBsAg or anti-HCV tests. * History of fainting upon blood sampling.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate and Extend of Absorption | 24 Hours |
Outcome results
None listed